Seeking Alpha

RJCogburn's  Instablog

RJCogburn
Send Message
I imagine myself as having the courage, determination, and loyalty as my screen name icon but will settle for two out of three. Retired, investing has become a wonderful avocation.
  • OPTR...Receives Milestone Payment From Cempra for Next-Generation Macrolide Antibiotic  1 comment
    Jul 10, 2010 7:27 AM | about stocks: OPTR
    OPTR's drug nearest to approval is fidaxomicin, a promising treatment for C. diff infection which is a growing problem with only a couple of current drug treatments.  Next in line is Purvel for infectious dirrahea.  Both these have completed two phase 3 trials.

    The news regarding a next generation macrolide was a bit of a surprise.  A successful phase one study resulted in a $500,000 payment to OPTR from Cempra Pharmaceuticals per a licensing agreement. 

    The company has promising drugs, but still a ways to go.  How to value the company is problematic and the stock price has been steadily dropping since mid March and trades near its one year low.
    Stocks: OPTR
Back To RJCogburn's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • Interesting. I don't really follow pharma companies, but will have to add this to my watch list. Thanks.
    22 Jan 2011, 09:15 AM Reply Like
Full index of posts »
Latest Followers

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.